Synthetic platelet storage media formulation

Details Synthetic platelet storage media formulation Synthetic platelet storage media formulation

2005-03-15

2005-03-15

Gitomer, Ralph (Department: 1651)

Chemistry: molecular biology and microbiology

Maintaining blood or sperm in a physiologically active state...

C604S004010, C604S020000

Reexamination Certificate

active

06866992

ABSTRACT:
Synthetic platelet storage media is disclosed for use with blood preparations intended for in vivo use. The synthetic platelet storage media is prepared by providing sodium chloride, sodium citrate, sodium acetate and sodium phosphate, and formulating in water 45-120 mM sodium chloride, 5-15 mM sodium citrate, 20-40 mM sodium acetate and 20-30 mM sodium phosphate.

REFERENCES:
patent: 2786014 (1957-03-01), Tullis
patent: 3629071 (1971-12-01), Sekhar
patent: 3729947 (1973-05-01), Higuchi
patent: 3735005 (1973-05-01), Shio et al.
patent: 3874384 (1975-04-01), Deindoerfer
patent: 4124598 (1978-11-01), Hearst et al.
patent: 4152208 (1979-05-01), Guirgis
patent: 4157723 (1979-06-01), Granzow
patent: 4169204 (1979-09-01), Hearst et al.
patent: 4196281 (1980-04-01), Hearst et al.
patent: 4265280 (1981-05-01), Ammann
patent: 4344936 (1982-08-01), Soslau et al.
patent: 4390619 (1983-06-01), Harmening-Pittiglio
patent: 4412835 (1983-11-01), Spencer
patent: 4447415 (1984-05-01), Rock et al.
patent: 4639373 (1987-01-01), Babior
patent: 4695460 (1987-09-01), Holme
patent: 4704352 (1987-11-01), Miripol
patent: 4727027 (1988-02-01), Wiesehahn
patent: 4748120 (1988-05-01), Wiesehahn et al.
patent: RE32874 (1989-02-01), Rock et al.
patent: 4828976 (1989-05-01), Murphy
patent: 4878891 (1989-11-01), Judy
patent: 4925665 (1990-05-01), Murphy
patent: 4960408 (1990-10-01), Klainer
patent: 4985153 (1991-01-01), Kuroda
patent: 4992363 (1991-02-01), Murphy
patent: 4994367 (1991-02-01), Bode et al.
patent: 5011695 (1991-04-01), Dichtelmuller
patent: 5055485 (1991-10-01), Geacintov
patent: 5100564 (1992-03-01), Pall
patent: 5112298 (1992-05-01), Prince
patent: 5120649 (1992-06-01), Horowitz
patent: 5234608 (1993-08-01), Duff
patent: 5234808 (1993-08-01), Murphy
patent: 5248506 (1993-09-01), Holme et al.
patent: 5288605 (1994-02-01), Lin et al.
patent: 5344752 (1994-09-01), Murphy
patent: 5372929 (1994-12-01), Cimino
patent: 5376524 (1994-12-01), Murphy
patent: 5399719 (1995-03-01), Wollowitz
patent: 5418130 (1995-05-01), Platz
patent: 5456845 (1995-10-01), Nishimura
patent: 5459030 (1995-10-01), Lin et al.
patent: 5466573 (1995-11-01), Murphy et al.
patent: 5474891 (1995-12-01), Murphy
patent: 5516629 (1996-05-01), Park
patent: 5556958 (1996-09-01), Carroll et al.
patent: 5559250 (1996-09-01), Cook et al.
patent: 5582828 (1996-12-01), Lin et al.
patent: 5593823 (1997-01-01), Wollowitz et al.
patent: 5618662 (1997-04-01), Lin et al.
patent: 5665762 (1997-09-01), Carroll et al.
patent: 5709991 (1998-01-01), Lin et al.
patent: 5712085 (1998-01-01), Wollowitz et al.
patent: 5908742 (1999-06-01), Lin et al.
patent: 6060233 (2000-05-01), Wiggins
patent: 6251580 (2001-06-01), Lin et al.
patent: 6566046 (2003-05-01), Lin et al.
patent: 20020009705 (2002-01-01), Lucas et al.
patent: 20020034722 (2002-03-01), Ericson et al.
patent: 20040029097 (2004-02-01), Goodrich et al.
patent: WO9103933 (1991-04-01), None
Adams G.A., and Rock G. “Storage of human platelet concentrates in an artificial medium without dextrose” Transfusion 28:217 (1988).
Adams, G.A. et al. “Survival and recovery of human platelets stored for five days in a non-plsma medium” Blood 67:672 (1986).
Alter et al. “Photochemical Decontamination of Blood Components Containing Hepatitis B and Non-A, Non-B Virus,” The Lancet (ii:1446-1450) (1988).
Artuc M., et al. “Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro” Brit. J. Derm. 101:669-677 (1979).
Belogurov and Zavil' gel'skii “Mechanism of the inactivation of the photosensitizer 8-Methoxypsoralen on bacteria and bacteriophages” Sovgenet 14:219-223 (1978).
Ben-Hur E. et al. “Measurement of DNA crosslinks by S1 nuclease: Induction and repair in psoralen plus 360 nm light treatedEscherichia coli,” Photochem. Photobio. 29:921 (1979).
Bertolini F. et al., “Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose free crystalloid medium” Transfusion 29:605 (1989).
Bertolini, F. et al., “Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium” Transfusion 32:9 (1992).
Bertolini, F. et al., “Platelet concentrates stored in synthetic medium after filtration,” Vox Sang 67:82-86 (1992).
Bode A.P. and Miller D.T. “Preservation of in vitro function of platelets stored in the presence of inhibitors of platelet activation and a specific inhibitor of thrombin” J. Lab Clin. Med. 111:118 (1988).
Boomgaard, M.N. et al. “In Vitro Evaluations of platelet concentrates, prepared from pooled buffy coats, stored for 8 days after filtration” Transfusion 34:311-316 (1994).
Bordin, F. et al. “5′Methylangelicin: a new highly photosensitizing angular furocoumarin” Experientia 35:1567 (1979).
Bridges, B.A. “8-methoxypsoralen and radiation damage in bacteria” Int'l. J. Rad. Bio. 20:185 (date not available).
Buchholz, D.H. et al. “Bacterial proliferation in platelet products stored at room temperature” New Eng. J. of Med. 285:429-433 (1971).
Buchholz, D.H. et al. “Detection and quantitation of bacteria in platelet products stored at ambient temperature” Transfusion 13:268-285 (1973).
Ciruino et al. “Psoralens as Photoactive Probes of Nucleic Acid Structure and Function: Organic Chemistry, Photochemistry, and Biochemistry,” Ann Rev. Biochem. 54:1151-1193 (1985).
Cordle et al. “The sterility of platelet and granalocyte concentrates collected by discontinuous flow centrifugation” Transfusion 30:105 (1980).
Dodd et al. “Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralen-ultraviolet A and merocyanine 540 visible light methods,” Transfusion 31:483-490 (1991).
Fijnheer R. et al. “In vitro evaluation of buffy coat derived platelet concentrates stored in a synthetic medium” Vox Sang. 659:77 (1990).
Friedman L and Stromberg R. “Viral inactivation and reduction in cellular blood products,” Rev. Fr. Transfus. Hemobiol. 36:83-91 (1993).
Fujita and Kakishima “Photobiological activities of 5-alkoxypsoralens with respect to the action onE coli” Photochem Photobio. 43:221 (1986).
Gaspairo et al. “Rapid and Sensitive Analysis of 8-MOP in Plasma” J. Invset. Derm. 90:234 (1988).
Grana et al. “Use of 8-methoxypsoralen and ultraviolet-A pretreated concentrates to prevent Iloimmunization against class I major histocompatibility antigens” Blood 77:2530 (1991).
Grossman, B.J. et al. “Screening blood donors for gastrointestinal illness: a strategy to eliminate carriers foYersinia enterocoliticia” Transfusion 31:500 (1991).
Gulliksson, H. et al. “A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with “Split” apheresis platelets” Transfusion Sci. 18:1 33-40 (1997).
Gulliksson, H. et al. “Buffy-coat-derived platelet concentrates prepared from half-strength citrate CPD and CPD whole-blood units” Vox Sanguinis 681 152-153 (1995).
Guppy M. et al. “Alternative fuels for platelet storage” Vox Sang 59(3):146 (1990).
Hass and Webb “8-methoxypsoralen effect on survival and repair ofescherichica coliafter ultraviolet irradiation: action spectra” Radiation Res. 80:170 (1979).
Heal, J.M. et al. “Fatalsalmonellasepticemia after platelet transfusion” Transfusion 27:2 (1987).
Hearst et al. “The Reaction of the Psoralens with Deoxyribonucleic Acid,” Quart. Rev. Biophys. 17:1-44 (1984).
Heaton et al. “Development of a combined storage medium for 7-day storage of platelet concentrates and 42-day storage of red cell concentrates” Brit. J. Haemotology 75:400 (1990).
Holme S et al. “Improved in vivo and in vitro viabilit

Affiliated with

Also associated with

Rating

Synthetic platelet storage media formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic platelet storage media formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic platelet storage media formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3452472